MarketPeel
Insider Trading Intelligence
JR

John C. Reed

JNJ
EVP, INNOVATIVE MEDICINE, R&D · JOHNSON & JOHNSON · CIK 0001181561
FILING MIX · LIFETIME44%/56%
BUYS
17
SELLS
22
TOTAL VALUE
$43.09M
COMPANIES
1
ACTIVE SINCE
May 2023
HOLDINGS NOW
35,913
AVG SELL PX
$195.07
TRADE KIND
SHOWING 39 / 39
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
5 backtested trades · 8 horizons · 13 pending
Forward-return performance of every backtestable P/S trade by John C. Reed, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d5+20.00%+1.24%+0.99%+0.26%+0.55%
14d5+20.00%+0.61%+0.44%+0.17%+1.77%
30d5+60.00%+0.92%-1.50%+2.42%+1.02%
60d5+60.00%+1.18%+3.88%-2.70%-7.76%
90d5+60.00%+2.63%+7.25%-4.61%-14.63%
180d5(3 pending)+0.00%+27.31%+7.91%+19.40%+19.40%
1y5(5 pending)
2y5(5 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
JNJ · 35,913 shares · as of May 1, 2026
022,44544,89167,33689,781202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 17 buys / 22 sellsCOVERAGE · 13 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
JNJ
JOHNSON & JOHNSON
SALE
EVP, Innovative Medicine, R&D
25,2550May 1, 2026May 4, 2026View →
JNJ
JOHNSON & JOHNSON
SALE
EVP, Innovative Medicine, R&D
11,002$229.85$2.53M24,911May 1, 2026May 4, 2026View →
JNJ
JOHNSON & JOHNSON
PURCHASE
EVP, Innovative Medicine, R&D
25,25535,913May 1, 2026May 4, 2026View →
JNJ
JOHNSON & JOHNSON
SALE
EVP, Innovative Medicine, R&D
29,92759,854Feb 17, 2026Feb 18, 2026View →
JNJ
JOHNSON & JOHNSON
PURCHASE
EVP, Innovative Medicine, R&D
21,721$157.92$3.43M34,662Feb 17, 2026Feb 18, 2026View →
JNJ
JOHNSON & JOHNSON
SALE
EVP, Innovative Medicine, R&D
21,721$243.00$5.28M12,941Feb 17, 2026Feb 18, 2026View →
JNJ
JOHNSON & JOHNSON
SALE
EVP, Innovative Medicine, R&D
29,927$243.00$7.27M12,941Feb 17, 2026Feb 18, 2026View →
JNJ
JOHNSON & JOHNSON
SALE
EVP, Innovative Medicine, R&D
2,283$243.00$554.8K10,658Feb 17, 2026Feb 18, 2026View →
JNJ
JOHNSON & JOHNSON
SALE
EVP, Innovative Medicine, R&D
21,72121,721Feb 17, 2026Feb 18, 2026View →
JNJ
JOHNSON & JOHNSON
PURCHASE
EVP, Innovative Medicine, R&D
29,927$156.15$4.67M42,868Feb 17, 2026Feb 18, 2026View →
JNJ
JOHNSON & JOHNSON
PURCHASE
EVP, Innovative Medicine, R&D
1,84713,469Feb 15, 2026Feb 18, 2026View →
JNJ
JOHNSON & JOHNSON
SALE
EVP, Innovative Medicine, R&D
1,8473,692Feb 15, 2026Feb 18, 2026View →
JNJ
JOHNSON & JOHNSON
PURCHASEGRANT
Stock grant
3,5463,546Feb 15, 2026Feb 18, 2026View →
JNJ
JOHNSON & JOHNSON
PURCHASE
EVP, Innovative Medicine, R&D
1,34912,007Feb 15, 2026Feb 18, 2026View →
JNJ
JOHNSON & JOHNSON
PURCHASEGRANT
Stock grant
49,38249,382Feb 15, 2026Feb 18, 2026View →
JNJ
JOHNSON & JOHNSON
SALE
EVP, Innovative Medicine, R&D
385$243.45$93.7K11,622Feb 15, 2026Feb 18, 2026View →
JNJ
JOHNSON & JOHNSON
SALE
EVP, Innovative Medicine, R&D
1,3491,349Feb 15, 2026Feb 18, 2026View →
JNJ
JOHNSON & JOHNSON
SALE
EVP, Innovative Medicine, R&D
528$243.45$128.5K12,941Feb 15, 2026Feb 18, 2026View →
JNJ
JOHNSON & JOHNSON
SALE
EVP, Innovative Medicine, R&D
21,721$192.71$4.19M10,658Oct 17, 2025Oct 20, 2025View →
JNJ
JOHNSON & JOHNSON
SALE
EVP, Innovative Medicine, R&D
21,721$157.92$3.43M43,442Oct 17, 2025Oct 20, 2025View →
JNJ
JOHNSON & JOHNSON
PURCHASE
EVP, Innovative Medicine, R&D
21,721$157.92$3.43M32,379Oct 17, 2025Oct 20, 2025View →
JNJ
JOHNSON & JOHNSON
SALE
EVP, Innovative Medicine, R&D
19,137$163.55$3.13M10,658Jul 17, 2025Jul 18, 2025View →
JNJ
JOHNSON & JOHNSON
SALE
EVP, Innovative Medicine, R&D
25,25525,255May 1, 2025May 5, 2025View →
JNJ
JOHNSON & JOHNSON
PURCHASE
EVP, Innovative Medicine, R&D
25,25540,797May 1, 2025May 5, 2025View →
JNJ
JOHNSON & JOHNSON
SALE
EVP, Innovative Medicine, R&D
11,002$156.31$1.72M29,795May 1, 2025May 5, 2025View →
JNJ
JOHNSON & JOHNSON
SALE
EVP, Innovative Medicine, R&D
385$156.15$60.1K15,542Feb 18, 2025Feb 18, 2025View →
JNJ
JOHNSON & JOHNSON
SALE
EVP, Innovative Medicine, R&D
1,3502,698Feb 15, 2025Feb 18, 2025View →
JNJ
JOHNSON & JOHNSON
PURCHASE
EVP, Innovative Medicine, R&D
1,35015,927Feb 15, 2025Feb 18, 2025View →
JNJ
JOHNSON & JOHNSON
PURCHASEGRANT
Stock grant
5,5395,539Feb 15, 2025Feb 19, 2025View →
JNJ
JOHNSON & JOHNSON
PURCHASEGRANT
Stock grant
89,78189,781Feb 15, 2025Feb 19, 2025View →
JNJ
JOHNSON & JOHNSON
SALE
EVP, Innovative Medicine, R&D
10,984$144.59$1.59M11,577May 1, 2024May 3, 2024View →
JNJ
JOHNSON & JOHNSON
SALE
EVP, Innovative Medicine, R&D
22,25553,510May 1, 2024May 3, 2024View →
JNJ
JOHNSON & JOHNSON
PURCHASE
EVP, Innovative Medicine, R&D
22,25522,561May 1, 2024May 3, 2024View →
JNJ
JOHNSON & JOHNSON
SALE
EVP, Innovative Medicine, R&D
25,25550,510May 1, 2024Oct 31, 2024View →
JNJ
JOHNSON & JOHNSON
SALE
EVP, Innovative Medicine, R&D
10,984$144.59$1.59M14,577May 1, 2024Oct 31, 2024View →
JNJ
JOHNSON & JOHNSON
PURCHASE
EVP, Innovative Medicine, R&D
25,25525,561May 1, 2024Oct 31, 2024View →
JNJ
JOHNSON & JOHNSON
PURCHASEGRANT
Stock grant
65,16365,163Feb 15, 2024Feb 20, 2024View →
JNJ
JOHNSON & JOHNSON
PURCHASEGRANT
Stock grant
4,0484,048Feb 15, 2024Feb 20, 2024View →
JNJ
JOHNSON & JOHNSON
PURCHASEGRANT
Stock grant
75,76575,765May 1, 2023May 2, 2023View →
Other insiders · JNJ
Loading peer insiders…
About this filer
CIK 0001181561
ROLE
EVP, Innovative Medicine, R&D
PRIMARY
JNJ
COMPANIES
1
ACTIVE SINCE
May 2023
MARKETPEEL · /INSIDER/0001181561DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback